# GH21 Combined With D-1553 in KRAS G12C Mutant Advanced Solid Tumors

> **NCT06435455** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Suzhou Genhouse Bio Co., Ltd.** · enrollment: 126 (estimated)

## Conditions studied

- Locally Advanced or Metastatic Solid Tumors Harboring KRAS G12C Mutation

## Interventions

- **DRUG:** GH21
- **DRUG:** D-1553

## Key facts

- **NCT ID:** NCT06435455
- **Lead sponsor:** Suzhou Genhouse Bio Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-07-01
- **Primary completion:** 2027-09-30
- **Final completion:** 2027-12-31
- **Target enrollment:** 126 (ESTIMATED)
- **Last updated:** 2024-07-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06435455

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06435455, "GH21 Combined With D-1553 in KRAS G12C Mutant Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06435455. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*